business
Biogen Publishes EMPAVELI Data Showing Reduced Proteinuria In Adolescents With Kidney Diseases
Biogen announced publication of adolescent subgroup data from Phase 3 VALIANT trial of EMPAVELI in rare kidney diseases. The drug achieved a 71% response rate for 50% proteinuria reduction, with safety consistent across trial populations.
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
US stocks: S&P 500 ends nearly flat as US-Iran talks help stocks pare losses
economictimes.indiatimes.com
McDonald’s offers US$8.5 billion to help owners with overhaul
financialpost.com
Carney tells NYT he looked at ‘extreme tail risk’ of U.S. invasion
financialpost.com
Former VC Partner Hsin-Ju Chuang Dies at 37: What We Know So far
Cryptonews
Form 8.5 (EPT/RI)-Pollen Street Group Limited
Globenewswire_fr